AXS26_DigitalGuide_Final pages - Flipbook - Page 29
For more than two decades, Alnylam has advanced
the Nobel Prize–winning science of RNAi, delivering
critical breakthroughs and six approved medicines.
Come join us and our esteemed Trend Report Payer Editors
2025 Alnylam Specialty & Rare
Disease Trend Report
APRIL 2026
This annual report offers a unique lens into payer
and plan decision-maker perspectives, providing
actionable insights into the evolving dynamics
of orphan drug access.
Scan the QR code to access this year’s report
summary. For additional details, please see the
AXS26 Agenda to learn more.
MONDAY, APRIL 27, 2026
|
RNAi=ribonucleic acid interference.
© 2026 Alnylam Pharmaceuticals, Inc. All rights reserved. NP-USA-01138
2:00 PM
|
ROOM: MARGAUX 2
